Pharmacoeconomics,
Epidemiology,
Pharmaceutical
Policy and
Outcomes
Research (PEPPOR)
Graduate Program
Back Row (right to Left): Akshay Kharat PhD Student, Vishvas Garg PhD
Candidate, Professor Dennis Raisch, Associate Professor Matthew Borrego,
Associate Professor Ludmila Bakhireva, Master's Student Renee Donohoe,
Master's Student Alex Woersching; Front row: Ghadeer Dawwas PhD Student,
Rasha Arabyat PhD Student, Melissa Roberts PhD Candidate, Mahek Garg
Master's Student, Khalid Al Moaikel PhD Student; Not Pictured: Ning Yan Gu
Assistant Professor, Luis Robles PhD Student, Yuebin Zhao PhD student
Grants & Awards
click HERE for a listing of our scholarly publications
| M.Sather | D. Raisch | N. Khan | M. Borrego | L. Bakhireva |
Ludmila Bakhireva, MD, PhD, MPH
Current:
5U01
AA-0148-35 Chambers (P.I.) 09/01/07-08/31/12
NIH/NIAAA
“Collaborative Initiative on Fetal Alcohol Spectrum Disorders: Spectrum of
and Nutritional Risk Factors for FASD in Russia and Ukraine.”
The main goals of this prospective study with a clinical trial component is
to more fully delineate the complete range of FASD expression and to test
the potential benefit of maternal second and third trimester supplementation
with micronutrients that may help ameliorate negative outcomes of prenatal
alcohol exposure.
Role: Co-investigator (15% effort)
5U24
AA-0148-15 Jones (P.I.) 09/01/07-08/31/12
NIH/NIAAA
“Collaborative Initiative on Fetal Alcohol Spectrum Disorders: Dysmorphology
Core.”
The main goal of this project is to provide a consistent evaluation of
children prenatally exposed to alcohol and unexposed comparison subjects.
Role: Co-investigator (5% effort)
Grant
Bakhireva/Young (co-P.I.s) 2008-2009
University of New Mexico Signature Program in Child Health Research.
“Barriers towards Adequate Treatment of Chronic Maternal Disorders during
Pregnancy and the Effect of Under-treatment on Adverse Neonatal Outcomes”.
The goal of this multi-center prospective study of pregnant women in New
Mexico is to ascertain patient- and provider-determined barriers toward
adequate treatment of chronic disorders in pregnancy and the effect of
poorly controlled maternal conditions on adverse perinatal outcomes.
Role: co-P.I./mentor
Grant
Bakhireva/Sarangarm (co-P.I.s) 2008-2009
University of New Mexico College of Pharmacy Pappiani’s Circle Fund.
“The Use of Over-The-Counter Medications and Perception of Teratogenicity in
Pregnant Women”.
The goal of this prospective study is to examine utilization of
over-the-counter (OTC) medications among pregnant women in New Mexico and to
determine patients’ perception about teratogenicity of OTC medications when
used in pregnancy.
Role: co-P.I./mentor
Completed:
Grant
Bakhireva (P.I.) 02/01/2008-01/31/2009
The American College of Clinical Pharmacy, Investigator Development Research
Award
“The Role of Statins in Prevention of Osteoporosis-related Fractures.”
The primary goal of this study is to examine the role of lipid-lowering
therapy in prevention of osteoporosis-related fractures using a large HMO
database.
Role: P.I.
5U01
AA14835-03 Chambers (P.I.) 09/30/03-09/28/08
NIH/NIAAA
“Collaborative Initiative on Fetal Alcohol Spectrum Disorders: Risk Factors
for FASD in the Moscow region”
This study investigates the pregnancy outcomes in women in the Moscow region
who report moderate to heavy alcohol consumption during pregnancy.
Role: Program Manager (60% effort)
5U24
AA14835-05 Jones (P.I.) 09/30/03-09/28/08
NIH/NIAAA
“Collaborative Initiative on Fetal Alcohol Spectrum Disorders: Dysmorphology
Core.”
The main goal of this project is to provide a consistent evaluation of
children prenatally exposed to alcohol and unexposed comparison subjects.
Role: Program Manager (40% effort)
Matthew Borrego, PhD
info coming soon
Nasreen Khan, PhD
Robert Wood
Johnson Foundation Center for Health Policy, University of New Mexico. Off
–label Use: The Case of Gabpentin. $10,000 (2009). Role: Principal
Investigator.
The Health Science Center Research Allocation Committee, University of New
Mexico . Effect of Prescription Drug Insurance on Prescription Drug Use
among Elderly Patients with Diabetes. $9,620 (2008-2009). Role: Principal
Investigator.
National Association of Chain Drug Stores (NACDS) Foundation. Evaluation of
Pharmacist-Delivered Medication Therapy Management Services to Chronically
Ill Medicare Patients in New Mexico. $100,000 (2008-2010). Role:
Investigator (PI: Melanie Dodd)
American Society of Health System Pharmacist. Comparison of Monotherapy with
Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers
in Preventing Vascular Disease and All-Cause Mortality among Veteran
Patients with Type 2 Diabetes $20,000 (2008-2009). Role: Senior Investigator
(PI: Heather Campbell):
Robert Wood Johnson Foundation Center for Health Policy, University of New
Mexico. Drug Coverage, Utilization and Health in the Rheumatoid Arthritic
Elderly Population. $10,000 (2007-2008). Role: Principal Investigator.
Dennis W. Raisch, PhD
Principal Investigator
A Randomized, Clinical Trial of the Use of Cimetidine for Pruritus Resulting from Epidural Morphine Analgesia. Smith, Kline, and French Laboratories; $10,000, 1987.
Factors Affecting Services Provided by Community Pharmacists to Improve Drug Prescribing and Use. University of New Mexico Research Allocation Committee Larger Grants; $5,880, March 1990 September 1990.
Developing Ambulatory Care Clinical Clerkship Training in Rural Communities. American Association of Colleges of Pharmacy, Grant Awards for Pharmacy Schools; $18,589, May 1991 December 1992.
Incorporating Problem Based, Student Centered Learning into Pharmacy Externship Rotations. American Association of Colleges of Pharmacy, Grant Awards for Pharmacy Schools; $24,871, May 1993 June 1994.
Development of a Remote Drug Treatment Information System (RDTIS) and Pharmacoeconomic Analysis of the RDTIS. National Institute on Drug Abuse, Co-Principal Investigator: Mark S. Jones; Co-Investigators: Mike R. Sather, $127,461, December, 1993 – January 1999
Pharmacoeconomic Substudy of the Prophylaxis of Medical Patients for Thromboembolism Study (PROMPT, CSP #438). Rhone Polenc Rorer, Co-Principal Investigator: Frank Lederle; $10,000, January 1999-December 2000.
Pharmacoeconomic Analysis Of Omeprazole Treatment After Lansoprazole Failure. Astra Merck HECON/PDEP, $5,000, May 1999-May 2000.
Utilization and Costs Associated with Pressure Wounds, Venous Leg Ulcer Wounds, Diabetic Foot Ulcer Wounds, and Other Chronic Ulcer Wounds in New Mexico Medicaid Patients. Pharm Ideas, Incorporated; Co-Principal Investigator: Gireesh V. Gupchup; $5,022, May 1999 - December 2000.
Determining Five Year Treatment Costs for VA Patients with Colorectal Cancer of the Sigmoid Colon. Pharmacia and Upjohn Company; Co-Principal Investigators: Crystal L Harris and Gireesh V. Gupchup; $2,000, May 2001 – May 2003.
Assessment of VA Criteria for Nonsterioidal Anti-Inflammatory Agents in VISN 18. Pharmacia and Upjohn Company; Co-Principal Investigator: Crystal L Harris; $20,566, May 2001 – May 2003.
Cost-Effectiveness of Anticoagulant Therapy To Prevent Venous Thromboembolism After Major Orthopedic Surgery Among Veterans Affairs Patients. Glaxo Smith Kline, Inc; Co-Investigator: Heather M, Campbell; $43,989, September 2005 to July 2008.
Systematic review of health professional-led diabetes lifestyle interventions. Robert Wood Johnson Foundation Center Awards, University of New Mexico. Co-Investigators: Matthew Borrego, Heather Campbell, Ladonna Garcia; $8,291, July 2007 to July 2008.
Gout Treatment in the Veterans Affairs Health Care System: A Study of Prescribing Quality Indicators, Patient Adherence, and Complications. Savient Pharmaceuticals, Inc. Co-Investigator: Heather M. Campbell, Nasreen Khan. $100,300, April 2008 to present.
Description of Safety Profile of Paclitaxel. Abraxis Pharmaceuticals, Inc. $99,806, December 2008 – Present.
Co-Investigator
Investigation of the Efficacy of IV Filgrastim in Reducing the Duration and Severity of Neutropenia and the Incidence of Infections in Pediatric Patients with High Risk B Lineage Leukemia or Diffuse Undifferentiated Non Hodgkin's Lymphoma. Amgen Pharmaceuticals; Principal Investigator: Mark T. Holdsworth; Co Investigators: Marilyn Duncan, Cathy Chavez, Dennis W. Raisch; $19,961, 1993 – 1999.
An Economic Evaluation of Quality of Care in Pediatric Patients Receiving an Ondansetron based Antiemetic Regimen for Home vs. Inpatient Chemotherapy Treatments. Glaxo Pharmaceuticals; Principal Investigator: Mark T. Holdsworth; Co Investigators: Dennis W. Raisch, Marilyn Duncan, Cathy Chavez, $21,205, 1994 - 1995.
Predicting And Understanding The Intention To Use Herbal Medicines Among Elderly Hispanic And Non-Hispanic Whites: Application Of The Theory Of Planned Behavior. American Association of Colleges of Pharmacy; Prinicipal Investigator: Gireesh V. Gupchup; Co-Investigators: Dennis W. Raisch, Ernest J. Dole; $9,966, 1999-March 2003.
Is Hydroxyurea Leukemogenic: A Review of the Evidence. Bristol-Myers Squibb Company; Principal Investigator: Charles L. Bennett, MD, PhD; Co-Investigators: Becca Newlin, Derek Nathan, Dennis W. Raisch; $4,000, 2001-2002.
Research on Adverse Drug Reactions and Reports (RADAR). National Cancer Institute; Principal Investigator: Charles L. Bennett, MD, PhD. Northwestern University Medical School; Co-investigator: Dennis W. Raisch; $74,884 in 2003-4, $73,530 in 2005-2006.
RADAR II, Multiple Myeloma. National Cancer Institute; Principal Investigator: Charles L. Bennett, MD, PhD. Northwestern University Medical School; Consultant: Dennis W. Raisch; $20,000 in 2008 and 2009.
Comparison of monotherapy with angiotensin converting enzyme inhibitors or angiotensin receptor blockers in preventing vascular disease events and all cause mortality among veteran patients with type II diabetes. Senior Investigator: Nasreen Khan, PhD. Universty of New Mexico College of Pharmacy. Junior Investigator: Heather M. Campbell, PharmD, Co-investigator: Dennis W. Raisch; $19,861, May 2008-present.
Mike R. Sather, PhD, FASHP
info coming soon
The
University of New Mexico’s Doctor of Pharmacy program is
accredited by the Accreditation Council for Pharmacy Education,
20 North Clark Street, Suite 2500, Chicago, IL 60602-5109, TEL
(312) 664-3575 , FAX (312) 664-4652,
URL
http://www.acpe-accredit.org/
01/30/2013 09:42:09 AM -0700.